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Abstract 
  Muscle atrophy occurs in many pathological states and results primarily from 
accelerated protein degradation by the ubiquitin-proteasome pathway. We used 
dexamethasone to induce muscle wasting and investigated the role of a microRNA 
(miRNA) in the control of muscle-specific E3 ubiquitin ligase MAFbx/atrogin-1. Here 
we show that miR-23a suppresses MAFbx/atrogin-1 translation by binding to 3’ UTR of 
the mRNA. Furthermore, ectopic expression of miR-23a is sufficient to protect 
myocytes from atrophy in vitro and in vivo in response to dexamethasone treatment, and 
heat stress-induced miR-23a protects muscle from dexamethasone-induced muscle 
atrophy.  Our surprising discovery of the physiological role of miR-23a in preventing 
the atrophy program should lay the basis not only for further understanding of the 
mechanisms of muscle wasting in diverse diseases, but also for developing novel 
therapies for these debilitating conditions.
INTRODUCTION 
  Adult skeletal muscle has tremendous plasticity at least in part due to a dynamic 
balance between protein synthesis and degradation. Increased protein synthesis leads to 
muscle hypertrophy, while increased protein degradation leads to muscle atrophy. 
Increased physical activity, particularly resistance training, induces muscle hypertrophy 
which is characterized by growth of the existing myofibers and often brings about 
health benefits. On the other hand, various chronic diseases result in skeletal muscle 
atrophy exacerbating the disease condition and compromising life quality. Therefore, 
preventing and attenuating skeletal muscle atrophy is one of important clinical issues. 
  Muscle atrophy occurs in response to fasting, chronic diseases (e.g., cancer, diabetes, 
AIDS, sepsis, and sarcopenia) and disuse. Under these diverse conditions, the 
atrophying muscles undergo accelerated protein degradation primarily through 
activation of the ubiquitin-proteasome pathway (1) and a common series of 
transcriptional adaptations that together constitute an “atrophy program” (2). In multiple 
models of skeletal muscle atrophy, the muscle-specific F-box protein MAFbx/atrogin-1 
is upregulated and appears to be essential for accelerated muscle protein loss (3). 
Overexpression of MAFbx/atrogin-1 in skeletal myotubes leads to atrophy, and mice 
deficient in MAFbx/atrogin-1 are resistant to various models of skeletal muscle atrophy 
(4, 5). 
  Sandri et al. reported that members of the class O of forkhead box transcription 
factors (FoxO) regulated MAFbx/atrogin-1 transcription (6). Atrophic factors induce 
FoxO expression and initiate its nuclear transport to enhance MAFbx/atrogin-1 
expression, which leads to muscle atrophy. On the other hand, PI3K/Akt signaling 
pathway, the major pathway of muscle hypertrophy, can prevent muscle atrophy by 
phosphorylating FoxO to inhibit its nuclear transport (7).  
  Recent studies have revealed a new aspect of muscle gene regulation in which small, 
noncoding RNAs, known as microRNAs (miRNAs), play fundamental roles in diverse 
biological and pathological processes, including differentiation and morphogenesis of 
skeletal muscle (8). miRNAs are approximately 22 nucleotides in length and inhibit 
translation of specific mRNA targets by interacting with the 3’ untranslated regions (3’ 
UTR) of the targets (9). miRNAs are primarily transcribed as pri-miRNAs, ranging in 
length from a few hundred to thousands of nucleotides with a characteristic hairpin 
secondary structure, and cleaved as pre-miRNAs by RNase III enzyme Drosha. Then 
pre-miRNAs are exported from nucleus by Exportin-5 and proccesed into ~22 
nucleotide miRNAs by RNase III enzyme Dicer. Finally, a single strand miRNAs are 
integrated into RNA-induced silencing complex (RISC), which directs miRNA binding 
the 3’ UTR of target mRNAs.  
  It has been reported that some miRNAs are expressed in a tissue-specific manner, 
which suggests roles of the miRNAs in the specification of the tissue during 
development. In the skeletal muscle, several muscle-specific miRNAs have been 
reported to play multiple roles in the control of muscle growth and differentation. Chen 
et al. (10) showed that muscle specific miRNAs, miR-1 and miR-133, down regulate 
serum responsive factor (SRF) and histone deacetylase 4 (HDAC4), respectively to 
control muscle differentiation. It has also been shown that myogenic regulatory factor, 
MyoD, induces miR-206 to promote myogenesis (11, 12). These previous studies have 
revealed the importance of muscle-specific miRNAs in skeletal muscle development; 
however there has no report on the function of miRNAs in adult skeletal muscle 
plasticity. Here we first report MAFbx/atrogin-1 gene regulation by miRNA to elucidate 
involvement of miRNA in muscle plasticity. Bioinformatics approach revealed potential 
target sites in the 3’ UTR of MAFbx/atrogin-1. We show that miR-23a binds to 3’ UTR 
of MAFbx/atrogin-1 to inhibit its translation, and forced expression of miR-23a in 
myotubes and myofibers results in resistance to muscle atrophy. Furthermore, we 
demonstrated that miR-23a is upregulated in response to physiological heat stress, 
which is potent in rendering protection against muscle atrophy in vitro and in vivo. 
These findings strongly support a functional role of miR-23a in muscle physiology and 
suggest a new therapeutic target in the setting of skeletal muscle atrophy. 
RESULTS 
miR-23a interacts with 3’ UTR of MAFbx/atrogin-1 mRNA. To investigate 
miRNA function in muscle atrophy, we employed bioinformatics to search for miRNAs 
that could potentially interact with MAFbx/atrogin-1. By using the online databases 
“Human miRNA targets” (http://cbio.mskcc.org/mirnaviewer/) and “miRBASE Targets” 
(http://microrna.sanger.ac.uk/targets/), we found miR-23a to be a strong candidate. 
miR-23a has been previously reported as a miRNA that is upregulated in the 
hypertrophy heart of mice with transgenic expression of activated calcineurin A (13). 
Our bioinformatics analysis revealed that the putative miR-23a binding site in 
MAFbx/atrogin-1 3’ UTR is highly conserved in mammals including human and mouse 
(Fig. 1a). To investigate functional interaction of miR-23a and MAFbx/atrogin-1, the 3’ 
UTR of MAFbx/atrogin-1 mRNA was subcloned into down stream of a luciferase 
reporter vector (Fig. 1b). miR-23a over expression vector (pCXbG-miR-23a) and the 
reporter vector (pLuc2EXN-atrogin-1 3’ UTR) were co-transfected into HeLa cells, and 
luciferase activity was measured 24 hours after the transfection. We also constructed a 
reporter vector with mutations on the putative miR-23a binding site of the 3’ UTR of 
MAFbx/atrogin-1 mRNA (pLuc2EXN-atrogin-1 3’ UTRΔ) and transfected as well as 
pLuc2EXN-atrogin-1 3’ UTR and pLuc2EXN. As expected, the luciferase activity from 
the pLuc2EXN-atrogin-1 3’ UTR was markedly reduced when co-transfected with 
miR-23a expression vector but not form the mutant vector (Fig. 1c), suggesting that 
miR-23a could interact with the 3’UTR to down regulate its expression. 
 
miR-23a leads to resistance to dexamethasone induced muscle atrophy in 
vitro and in vivo. We investigated miR-23a function by using an in vitro model of 
muscle atrophy with forced expression of miR-23a. A miR-23a experession vector, 
pCXbG-miR-23a, was transfected into a mouse myoblast cell line (C2C12) followed by 
induction of myogenesis (Supplementary Fig. 1). The myotubes were then treated with 
10 μM dexamethasone (Dex) for 24 hours and the diameters were measured by 
visualization of GFP as a transgene marker. In mock transfected cells, myotube diameter 
decreased significantly in response to Dex treatment. (Fig. 2a). On the other hand, the 
diameter of miR-23a expressing myotube did not decrease in response to Dex treatment. 
Dexamethasone-induced upregulation of MAFbx/atrogin-1 at transcriptional level was 
not affected by miR-23a expression (Fig. 2b), suggesting miR-23a mediates its function 
through other mechanisms than transcription. Furthermore, when we used electric pulse 
mediated gene transfer to transfect pCXbG-miR-23a into adult skeletal muscle in mice, 
we found that miR-23a-tranfected muscle showed less muscle weight loss than 
mock-transfected muscle in response to 7-day Dex treatment (daily with i.p. injection) 
(Fig. 3a) because miR-23a transfected myofibers became resistant to atrophy (Fig. 3b). 
Here, we measured cross sectional area of fast-twitch muscle fibers because 
glucocorticoid is known to induce muscle atrophy in fast twitch fibers selectively (14). 
In mock transfected muscle, cross sectional area of the fibers decreased significantly 
due to dexamethasone treatment, while miR-23a positive fibers were obviously resistant 
to muscle atrophy (Fig. 3b). These results suggest collectively that miR-23a expression 
is sufficient to attenuate skeletal muscle atrophy in vitro and in vivo.  
 
Heat stress activates miR-23a expression and attenuates muscle atrophy. 
miR-23a was reported as one of stress responsive miRNAs in cardiac muscle (13) and, 
therefore, it is possible that miR-23a is also induced by stress in skeletal muscle. We 
screened several physical stresses to induce miR-23a in vitro and found that heat stress 
has most striking effect to induce miR-23a in myoblasts (data not shown). This 
preliminary finding prompted us to investigate the potential role of heat stress-induced 
miR-23a in protection against muscle atrophy. We obtained exciting new evidence that 
heat stress renders myotubes resistant to dexamethasone-induced atrophy (Fig. 4a, b) 
without affecting MAFbx/atrogin-1 mRNA expression (Fig. 4b). To knockdown heat 
stress-induced miR-23a, locked nucleic acid (LNA) antisense against miR-23a was 
transfected into C2C12. The LNA antisense was reported to bind to miRNAs selectively 
and down-regulate their function by forming rigid duplex with their complementary 
miRNAs (15). LNA antisense down-regulated miR-23a expression (Supplementary 
Fig. 2) and counteracted heat stress-induced atrophy resistance (Fig. 4b, c). These 
results showed that miR-23a was concerned with resistance against muscle atrophy 
induced by heat stress.  
 To ascertain the functional role of heat stress-induced resistance to muscle atrophy in 
vivo, we subjected mice to heat stress followed by dexamethasone treatment for 7 days. 
In fast-twitch plantaris muscle, muscle weight loss was significantly lower in heat stress 
exposed group than that of unexposed group (Fig. 4d). The cross sectional areas of 
fast-twitch fibers were also measured to reveal that the fiber size decrease was 
significantly lower in heat stress exposed group than that of unexposed group (Fig. 4e). 
Again, dexamethasone-induced MAFbx/atrogin-1 mRNA expression was not affected 
by heat stress (Supplementary Fig. 3). Consistent with our findings in cultured 
myotubes, miR-23a expression in skeletal muscle was significantly upregulated in mice 
exposed to heat stress (Fig. 4f). These results suggest that heat stress-induced miR-23a 
represses MAFbx/atrogin-1 expression post-transcriptionally to attenuate muscle 
atrophy. 
 
DISCUSSION 
  This study demonstrates that miR-23a is a novel regulator of MAFbx/atrogin-1 
through post-transcriptional regulation of the gene, playing a substantial role in 
protection against skeletal muscle atrophy. We showed here miR-23a interacts with 
MAFbx/atrogin-1 3’ UTR and forced expression of miR-23a in cultured myotubes and 
adult skeletal muscle results in resistance to glucocorticoid-induced muscle atrophy. We 
have also linked these new findings to a physiological setting of heat stress-induced 
protection against muscle atrophy. These findings strongly support that miR-23a 
functions in skeletal muscle by regulating the MAFbx/atrogin-1 gene in response to 
wasting and present a viable therapeutic target for this important clinically relevant 
problem that could be affected by and exacerbate many chronic diseases. 
  Recently, people start to pay more and more attention to the functional role of stress 
responsive miRNAs (16). Various types of stresses have been reported to induce 
miRNAs (17, 18), which have been clearly demonstrated in the cardiac muscles. 
Pressure overload or calcineurin activation induces pathological cardiac hypertrophy 
(20, 21), in which miR-195 and miR-208 play important roles (13, 19). Upon such 
hypertrophic stress, several miRNAs including miR-23a were upregulated, and miR-23a 
overexpression in cardiomyocytes evoked myocyte hypertrophy (13). In the skeletal 
muscle, overexpression of miR23a did not lead to hypertrophy, but resistance against 
dexamethasone-induced atrophy (Fig. 3). Together with findings in this study, it remains 
formally possible that miR-23a plays an anti-atrophic effect on skeletal muscle. The 
apparent protection observed in vivo in our study could be a result of the mechanism. 
  We screened several physiological stresses to identify the one that heat stress could 
profoundly upregulate miR-23a expression in C2C12 myoblasts. Since miR-23a 
expression was sufficient to induce hypertrophy in cardiomyocyte, it is also possible 
that miR-23a induces significant muscle hypertrophy. Our results in culture myotubes 
clearly demonstrate that miR-23a does not promote muscle hypertrophy in vitro, but 
prevent myotubes from atrophy (Fig. 2a). Notably, heat stress renders myotubes 
resistant to glucocorticoid-induced atrophy without affecting the induction of 
MAFbx/atrogin-1 mRNA. LNA antisense mediated miR-23a silencing counteracted 
heat stress-induced resistance of muscle atrophy. In addition, heat stress also activated 
miR-23a expression in vivo and protected skeletal muscle from atrophy. These results 
suggest that stress inducible miR-23a down regulates MAFbx/atrogin-1 
post-transcriptionally and protect muscle from atrophy. 
  Previous study suggested that heat shock proteins (HSPs) play a role in muscle 
atrophy attenuation by heat stress (22). HSPs serve as molecular chaperones in refolding, 
disaggregation, and degradation of damaged polypeptides induced by various stresses 
including heat stress. Our results suggest that heat stress-induced miR-23a inhibits 
protein degradation by suppressing the proteasome system via down-regulation of the 
MAFbx/atrogin-1expression.  
  Regulations of miRNAs are attractive targets for clinical therapies. Several miRNAs 
have been shown to be important in disease development, such as cancer (23，24), heart 
disease (13) and cholesterol/lipid metabolism (25). Our results suggest that miR-23a has 
the potency to attenuate muscle atrophy. Therapeutic manipulation of miR-23a 
expression could potentially maintain skeletal muscle function by suppressing 
MAFbx/atrogin-1 expression.  
  Although we have shown that miR-23a is induced by heat stress, its transcriptional 
control has yet to be determined. It has been reported that miR-23a is included in a 
polycistronic miRNA cluster, in which two or three miRNAs are generated from a 
common pri-miRNA, together with miR-27a and miR-24-2 (26), which is conserved 
from zebrafish to human. Such unique transcriptional control is thought to contribute to 
a highly coordinated regulation of miRNA target genes. Interestingly, miR-23b, which 
has similarity with miR-23a, is also in this polycistronic miRNA cluster. Elucidation of 
transcriptional control this super cluster miRNA might offer significant insights into the 
physiological meaning of stress responsive miRNAs. 
METHODS 
Cell culture. C2C12 (American Type Culture Collection) mouse skeletal myoblasts 
were maintained at subconfluent densities in 20% FBS in DMEM (GM). At 80-100% 
confluent density, medium was changed to 2% horse serum (HS) in DMEM (DM) and 
myogenesis was induced. After 4 days incubation with DM, more than 80% cells 
formed multi-nuclear myotube. To induce muscle atrophy in vitro, cells were incubated 
with 10 μM dexamethasone (Dex) in DM for 12 hours or 24 hours. After the treatment, 
cells were harvested with appropriate buffers or used for morphological analysis.  
 
Myotube morphological analysis. After the Dex treatment, myotubes were stained 
with Hoechist 33342 (Invitrogen Co., Carlsbad, CA) for nucleus and cell tracker green 
fluorescent (Lonza Group Ltd., Basel, Switzerland) for cytoplasm and photographed 
directly in culture plates by using IX71 fluorescent microscope (Olympus, Tokyo, 
Japan) with EM-CCD digital camera (Hamamatsu Photonics K.K., Shizuoka, Japan). 
More than 50 myotubes’ diameter was measured by AquaCosmos software (Hamamatsu 
Photonics K.K.). 
 
Vectors. pCXbG-miR-23a; A primary miR-23a region was amplified by PCR using 
human genomic DNA with primers: 5’-AAA GTC GAC CTT TCT CCC CTC CAG 
GTG C-3’ and 5’-AAG ATA TCT CGA GAC AGG CTT CGG GGC CTC TC-3’. The 
PCR product was digested with SalI plus EcoRV and introduced into plasmid pCXbG at 
XhoI plus EcoRV sites. The pCXbG was generated from plasmid pCX-EGFP (27). The 
DNA fragment including the EGFP fused with blasticidin resistant gene and XhoI and 
EcoRV sites was amplified by PCR using the pTracerEF-Bsd (Invitrogen) and pEGFP 
(Clontech Laboratories, Inc., Mountain View, CA) as templates and it was inserted into 
the EcoRI sites of pCX-EGFP to yield the pCXbG. pLuc2EXN-atrogin-1 3’UTR; A 300 
bp nucleotide fragment of the MAFbx/atrogin-1 3’UTR, including a putative miR-23a 
binding site, was amplified from mouse cDNA by PCR using Ex Taq HS (TaKaRa, 
Osaka, Japan). Primer sequences are as follows; forward primer: 5’-TCT CTA GAA 
TCC CAG CAC ACG ACA ACA CTT C-3’; reverse primer: 5’-CTC TCG AGG ACT 
CCG TTT CCA TGG CTG AC-3’. Amplified fragments were cloned into the EcoRI and 
XbaI sites of pLuc2EXN plasmid. The pLuc2EXN was generated from a plasmid 
pGL3-control to clone Luc2 gene (Promega Co., Madison, WI) ahead of additional 
EcoRI and XbaI sites. pLuc2EXN-atrogin-1 3’UTRΔ was generated by site-direct 
mutagenesis from pLuc2EXN-atrogin-1 3’UTR as described previously (28). Briefly, a 
forward primer, 5'- GCC GAT GGA AAT TTA CAC ACT ATA ATT CCA CAT G -3', 
and a reverse primer, 5'- CAT GTG GAA TTA TAG TGT GTA AAT TTC CAT CGG C 
-3', (mutated nucleotides are underlined) were used in a PCR-based site-directed 
mutagenesis using the QuickExchange lightning sited-directed mutagenesis kit 
(Stratagene). All plasmid DNAs were transformed and amplified in DH-5α bacteria, 
purified using the plasmid Midi kit (Qiagen). 
 
Transfection. C2C12 were seeded in 6-well plates 24 hours before transfection. Cells 
were transfected with 1 μg of each vector or 50 ng of locked nucleic acid (LNA; 
underlined) antisense, 5'- AUC ACA UUG CCA GGG AUU UCC -3', with 
Lipofectamine 2000 (Invitrogen) in serum free Opti-MEM (Invitrogen). Medium was 
changed to medium containing FBS after 6 hours incubation.   
 
Reporter assay. HeLa cells (ATCC) were seeded in 6-well plates 24 hours before 
transfection. Cells were transfected with 0.1 μg of pLuc2EXN-atrogin-1 3’UTR, 0.1 μg 
of LacZ and 1.8 μg of pCXbG-miR-23a with Lipofectamine 2000. Cells were lysed 24 
hours after the transfection, and luciferase activity was measured using luciferase 
reporter assay system (Promega Co). Luciferase activity was normalized by LacZ 
activity as described (29). 
 
RNA analysis. According to manufacturers’ protocols, total RNA was extracted from 
cells and animal tissues by using ISOGEN (WAKO, Osaka, Japan) and 10 μg of RNA 
was subjected to reverse transcription (RT) by using SuperScript III (Invitrogen). Oligo 
dT primers were used to generate cDNA and an aliquot of the RT reaction was used 
directly for PCR with Ex Taq HS (TaKaRa, Osaka, Japan) and gene-specific primers. 
The primer sequences are as follows: MAFbx/atrogin-1, 5’-GGG AGG CAA TGT CTG 
TGT TT-3’ and 5’-TTG TGA AAA AGT CCC GGT TC-3’; GAPDH, 5’-GTG GCA 
AAG TGG AGA TTG TTG CC-3’ and 5’-GAT GAT GAC CCG TTT GGC TCC-3’. 
GAPDH was used as an internal standard. 
 
MicroRNA analysis. TaqMan MicroRNA Reverse Transcription Kit and TaqMan 
MicroRNA assays (Applied Biosystems, Foster City, CA) were used to quantify 
expression of mature miRNAs according to manufacturer’s protocol. In miRNA 
quantification, each reverse transcriptase (RT) reaction contained 10 ng of purified total 
RNA. The reactions were incubated for 30 min at 16 °C, 30 min at 42 °C, and 5 min at 
85°C. Real-time PCR reactions for each miRNA (10 μl volume) were performed in 
triplicate, and each 10 μl reaction mixture included 2 μl of diluted RT product. 
Reactions were incubated in an Applied Biosystems 7500 Fast Real-Time PCR system 
in 96-well plates at 95°C for 10 min, followed by 40 cycles at 95°C for 15 s and 60°C 
for 1 min.  
 
Animal experiments. Adult (8 weeks of age) male C57BL/6 mice (Clea Japan, Inc., 
Tokyo, Japan) were housed in temperature-controlled quarter (21˚C) with a 12-h 
light/12-h dark cycle and provided with water and chow ad libitum. To induce skeletal 
muscle atrophy, 1 mg Dex/kg body weight was injected intraperitonealy for 7 days. 
After Dex treatment, animals were sacrificed and muscles were harvested with 
appropriate buffer or embedded with O.C.T. compound. The animal protocols were 
approved by the Animal Care and Use Committees, the University of Tokyo and Waseda 
University. 
 
Immunohistochemistry. Anti-myosin heavy chain (MHC) 2a (SC-71) and 2b (BF-F3) 
monoclonal antibodies were used as primary antibodies for immunostaining of O.C.T. 
-embedded cross sections from mice skeletal muscle (30). Mouse anti-dystrophin 
antibody (D8043, Sigma, St. Louis, MO) with FITC-conjugated secondary antibody was 
used to identify shapes of muscle fibers. Cross sections were fixed in PBS with 4% 
paraformaldehyde, then permeabilized in PBS with 0.3% Triton X-100, and incubated 
with each primary Ab for overnight. The secondary antibodies were either FITC 
conjugated anti-mouse IgG or R-PE conjugated anti-mouse IgM (for MHC 2a and MHC 
2b, respectively; Jackson ImmunoResearch Laboratories, Inc., West Grove, PA). Finally, 
cover slips were enclosed with VECTA SHIELD (Vector Laboratories, Ltd., Burlingame, 
CA). Cross sectional area was measured by AquaCosmos software (Hamamatsu 
Photonics K.K.). 
 
Electric pulse-mediated gene transfer. Electric pulse-mediated gene transfer was 
performed as described (28). Briefly, both tibialis anterior (TA) muscles were injected 
with 20 μg of plasmid DNA under anesthesia (50 mg/kg i.p. pentobarbital sodium). 
Within 1 min after injection, electrical field was delivered to the injected TA muscle by 
SEN-3401 electric stimulator (Nihon Kohden, Tokyo, Japan) through a model 532 
two-needle array (BTX Instrument Division Harvard Apparatus, Inc., Holliston, MA). 
Eight pulses at 100 ms in duration, 1 Hz in frequency, and 100 V in amplitude (200 
V/cm) were applied to the muscle by placing the needle arrays on the medial and lateral 
sides of the TA muscle so that the electrical field was perpendicular to the long axis of 
the myofibers. The mice were allowed to recover for 4 days before dexamethasone 
injection.  
 
Heat stress exposure. For in vitro study, C2C12 myotubes were exposed to heat stress 
on a water bath (42°C) for 30 mins. To induce muscle atrophy in vitro, medium was 
changed to DM containing 10 μM Dex for 12 hours after the heat stress exposure. For in 
vivo study, the mice were exposed to heat stress at 42°C for 1 hour. After 24 hours of 
heat stress exposure, 1 mg Dex/kg body weight was injected intraperitonealy to induce 
skeletal muscle atrophy. Dex was injected once a day for 7 days. 
 
URLs. “Human miRNA targets”: http://cbio.mskcc.org/mirnaviewer/. “miRBASE 
Targets”: http://microrna.sanger.ac.uk/targets/.  
 
Statistics. Data are expressed as the means ± standard errors of the means. Statistical 
significance (P < 0.05) was determined by Student’s t-test or ANOVA followed by the 
Dunnett test for comparisons between two groups or multiple groups, respectively. 
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Figure Legends 
 
Figure 1 
miR-23a targets MAFbx/atrogin-1 3’ UTR. (a) Sequence alignment of putative 
miR-23a binding site in 3’ UTR of MAFbx/atrogin-1 shows a high level of 
complementarity and sequence conservation. (b) A reporter vector construct of 
Luc-atrogin-1 3’ UTR. To analyze miR-23a function, MAFbx/atrogin-1 3’ UTR 
including miR-23a putative binding site was cloned into the down stream of luciferase 
expression vector. (c) HeLa cells were cotransfected with either Luc-atrogin-1 3’ UTR 
(WT), Luc-atrogin-1 3’ UTRΔ, a mutant reporter vector (mutant) or original vector 
(control), along with miR-23a expression vector or mock vector. Luciferase activity was 
measured (n = 6). Values indicate luciferase activity relative to mock-cotransfected 
condition. * P < 0.001. Error bars mean ±SEM. 
 
Figure 2 
Forced expression of miR-23a counteracted dexamethasone-induced muscle 
atrophy. (a) miR-23a expression vector was transfected into C2C12 cells and 
myogenesis was induced. After 10 μM dexamethasone treatment (Dex), myotube 
diameter was measured (n > 50). The bar indicates 10 μm. (b) MAFbx/atrogin-1 mRNA 
expression was quantified by using real-time PCR (n = 6). Values are relative to mock 
control. * P < 0.05, ** P < 0.01. Error bars mean ±SEM. 
 
Figure 3 
Forced expression of miR-23a in adult muscle fibers counteracted 
dexamethasone-induced muscle atrophy. (a) Muscle weight (n = 8) and (b) cross 
sectional areas (CSA) of fast-twitch muscle fibers (MHC2b; Red) with or without 
miR-23a expression vector (Green; n > 80) were measured. Expression vectors for 
miR-23a or mock were transfected into TA muscle by the electric pulse-mediated gene 
transfer. The bar indicates 10 μm. * P < 0.001. Error bars mean ±SEM. 
 
Figure 4 
Heat stress exposed myotubes/muscle fibers show resistance against muscle 
atrophy. After heat stress exposure, myotubes were treated with Dex. (a) Myotubes 
were stained with cell tracker green (Green) and Hoechist 33342 (Blue), then their 
diameters were measured (n > 100). (b) Heat stress-induced MAFbx/atrogin-1 mRNA 
expression was measure in C2C12 cells with/without Dex-treatment. (c) Heat stress 
upregulated miR-23a expression in vitro. (d) For in vivo experiment, mice were injected 
dexamethasone for 7 days (H/Dex) 24 hours after heat stress, and sacrificed to measure 
muscle weight. (e) Cross sectional area (CSA) of fast-twitch fibers (MHC2b; Red) was 
measured. Bar indicates 200 μm. (f) Heat stress upregulated miR-23a expression in 
mice skeletal muscle. miR-23a expression was measured by using real-time PCR. 
Values are relative to control. * P < 0.05, ** P < 0.01. Error bars mean ±SEM. 
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